Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
Peptide blend
Tesamorlin + Ipamorelin
In stock
A two-component GHRH-analogue and secretagogue-peptide research blend.
Order within — · ships Wed, 23 Sep Cutoff 10:00 · local time
Arrives Sep 28 - Sep 30 to Europe
More at checkout
Tesamorlin + Ipamorelin
99,00 €
Tesamorelin and Ipamorelin blend for paired GHRH and GHSR pathway studies.
Research overview
Tesamorlin + Ipamorelin
Tesamorelin + Ipamorelin combines a stabilized GHRH analogue with the pentapeptide Ipamorelin.
Each component retains its own sequence, receptor context, and analytical identity within the declared blend. The listed sources are a research starting point rather than a substitute for product evidence: the supplied material's exact form, lot, and measured characteristics must be established through its signed analytical record.
Compound information
Specifications
Molecular profile
- Sequence
- Tesamorelin: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2; Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Molecular mass
- Tesamorelin: 5135.9 g/mol; Ipamorelin: 711.9 g/mol.
- CAS number
- Tesamorelin: 218949-48-5; Ipamorelin: 170851-70-4.
- Molecular formula
- Tesamorelin: C221H366N72O67S; Ipamorelin: C38H49N9O5.
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- Two-component research blend supplied strictly for research use only.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Tests
Documentation is available on request
Contact us for the current record for this strength. We never substitute a generic or mismatched certificate.
Your batch is confirmed when your order is allocated.Source record
References
National Center for Biotechnology Information
PubChem Compound Summary: Tesamorelin
Identity record for the Tesamorelin component.
PubChem · View source ↗National Center for Biotechnology Information
PubChem Compound Summary: Ipamorelin
Identity record for the Ipamorelin component.
PubChem · View source ↗Russo SC, Ockene MW, Arpante AK, et al. · 2024
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Primary clinical research report for the Tesamorelin component.
AIDS · 10.1097/qad.0000000000003965 View source ↗Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S · 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
The Journal of clinical endocrinology and metabolism · View source ↗Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK · 2019
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
The lancet. HIV · View source ↗Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV · 2012
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
Archives of neurology · View source ↗Lauritzen L, Amundsen ID, Damsgaard CT, Lind MV, Schnurr TM, Hansen T, Michaelsen KF, Vogel U · 2019
FADS and PPARG2 Single Nucleotide Polymorphisms are Associated with Plasma Lipids in 9-Mo-Old Infants
The Journal of nutrition · View source ↗Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee JJ, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JD, Speicher DW, Mastio J, Gimotty PA, Xu X, Wherry EJ, Gabrilovich DI, Amaravadi RK · 2020
PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma
JCI insight · View source ↗Customer reviews
Continue exploring
